Eli Lilly (LLY)
(Real Time Quote from BATS)
$736.64 USD
-19.27 (-2.55%)
Updated May 3, 2024 12:03 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 736.64 -19.27(-2.55%)
Will LLY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Season: 3 Companies Boosting Guidance
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Company News for May 1, 2024
Other News for LLY
Amgen price target raised by $10 at BofA, here's why
Amgen stock rallies 13% on GLP-1 weight-loss drug update
Unveiling Eli Lilly and Co (LLY)'s Value: Is It Really Priced Right? A Comprehensive Guide
Amgen ‘very encouraged’ by data from weight-loss-drug trial, as stock jumps
GLOBAL BROKER RATINGS: DZ Bank cuts Starbucks, CFRA raises Qualcomm